FilingSEC EDGAR6-K
Kazia Therapeutics Announces Approximately $40 Million Public Offering.
· SEC accepted
StageClinical Development
Filing content
Kazia Therapeutics plans to use the proceeds from its approximately $40 million ADS and warrant offering to fund the clinical development of paxalisib.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…